Assessment of extra-renal effects of SGLT2-inhibitors in anuric haemodialysis patients using microneurography

Phase 2

• Conditions: End Stage Kidney Disease (ESKD) with Anuria; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12623001237673
• Lead Sponsor: Dobney Hypertension Centre

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-30
• Last Update Posted: 12 December 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

•Adults 18 years and older
•Anuric haemodialysis patients
•Able to mobilise independently
•BP <160/90 mmHg

Exclusion Criteria

•Patients with Type 1 Diabetes
•Patients on SGLT2-inhbitors prior to the study will be excluded.
•History of Unilateral or Bilateral Nephrectomy, chronic liver disease, heart failure [New York Heart Association (NYHA) class II-IV}, or secondary hypertension
•Pregnancy (females of childbearing potential must have negative pregnancy test)
•Relative or absolute contraindication to empagliflozin, including active urinary or genital tract infection, or known drug allergy
•Severe peripheral vascular disease or neuropathy
•Initiation of alpha-blockers, beta-blockers or moxonidine within the preceding 6 weeks
•Cardiovascular event(s) within the last 6 months
•Unstable psychiatric condition or inability to understand and attend appointments
•On medications such as corticosteroids, multiple antidepressants, and antipsychotics

Study & Design

• Study Type: Interventional
• Study Design: Not specified